JP2025515497A5 - - Google Patents

Info

Publication number
JP2025515497A5
JP2025515497A5 JP2024563644A JP2024563644A JP2025515497A5 JP 2025515497 A5 JP2025515497 A5 JP 2025515497A5 JP 2024563644 A JP2024563644 A JP 2024563644A JP 2024563644 A JP2024563644 A JP 2024563644A JP 2025515497 A5 JP2025515497 A5 JP 2025515497A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
fragment
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020351 external-priority patent/WO2023212293A1/en
Publication of JP2025515497A publication Critical patent/JP2025515497A/ja
Publication of JP2025515497A5 publication Critical patent/JP2025515497A5/ja
Pending legal-status Critical Current

Links

JP2024563644A 2022-04-29 2023-04-28 補体h因子関連4特異的抗体及びその使用 Pending JP2025515497A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336751P 2022-04-29 2022-04-29
US63/336,751 2022-04-29
PCT/US2023/020351 WO2023212293A1 (en) 2022-04-29 2023-04-28 Complement factor h related 4-specific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025515497A JP2025515497A (ja) 2025-05-15
JP2025515497A5 true JP2025515497A5 (enExample) 2026-05-12

Family

ID=86424821

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563644A Pending JP2025515497A (ja) 2022-04-29 2023-04-28 補体h因子関連4特異的抗体及びその使用

Country Status (11)

Country Link
US (1) US20250289873A1 (enExample)
EP (1) EP4514844A1 (enExample)
JP (1) JP2025515497A (enExample)
KR (1) KR20250021400A (enExample)
CN (1) CN119365485A (enExample)
AU (1) AU2023260822A1 (enExample)
CA (1) CA3250483A1 (enExample)
CL (1) CL2024003283A1 (enExample)
IL (1) IL316610A (enExample)
MX (1) MX2024013188A (enExample)
WO (1) WO2023212293A1 (enExample)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
EP1002078A1 (en) 1997-07-31 2000-05-24 Chiron Corporation Method enabling readministration of aav vector via immunosuppresion of host
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
FR2785281B1 (fr) 1999-07-05 2001-04-27 Ugimag Sa Procede de fabrication de poudres ou biscuits d'hexaferrites de type m
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
PL2357189T3 (pl) 2003-06-19 2017-08-31 Genzyme Corporation Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
EA037120B1 (ru) 2015-02-02 2021-02-09 МЕИРЭДжТиЭкс ЮКей II ЛИМИТЕД Регулирование экспрессии генов посредством аптамер-опосредованного модулирования альтернативного сплайсинга
US20160346359A1 (en) 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
CA3019126A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
US20210371877A1 (en) 2017-12-18 2021-12-02 Spark Therapeutics, Inc. Adeno-associated virus (aav) vector lipid nanoparticle compositions and methods of use
EP3784697A4 (en) 2018-04-27 2022-07-06 Spark Therapeutics, Inc. GMO AAV CAPSIDS WITH INCREASED TROPISM AND AAV VECTORS CONTAINING THE GMO CAPSIDS, AND METHODS FOR THEIR MANUFACTURE AND USE
JP2021522813A (ja) 2018-05-07 2021-09-02 スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. プラスミドを用いないaavベクター産生細胞株
CN112470003A (zh) * 2018-05-10 2021-03-09 曼彻斯特大学 评估黄斑变性的方法
BR112021009452A2 (pt) 2018-11-16 2021-08-17 Spark Therapeutics, Inc. ensaio in vitro para detectar intensificadores e inibidores de transdução de vetor de vírus adeno-associados (aav) e/ou detectar ou quantificar anticorpos de ligação a anti-aav

Similar Documents

Publication Publication Date Title
JP2025514437A5 (enExample)
US9416182B2 (en) Anti-TNF-anti-IL-17 bispecific antibodies
JP2021036888A (ja) 二重特異性抗vegf/抗ang−2抗体及び眼血管疾患の処置におけるそれらの使用
TWI890481B (zh) 雙特異性抗體
EP3581245A1 (en) Antibodies to tau and uses thereof
JP2022122865A5 (enExample)
TW202241966A (zh) 對於介白素-4受體及介白素-31具特異性之多特異性抗體
JP2021514670A5 (enExample)
CN106565840A (zh) 抗乙肝表面抗原的抗体及其用途
JP2023534214A5 (enExample)
JP2023130473A (ja) 眼又は眼疾患を処置するための抗セマフォリン3a抗体及びその使用
KR20260030123A (ko) 혈액 뇌 장벽을 통과하여 그라눌린을 전달하기 위한 화합물
US20230406942A1 (en) Igf1r antibodies
JP2024523514A5 (enExample)
JP2025517111A5 (enExample)
JP2020534307A (ja) 抗体変異体
JP2025525442A (ja) Ang2/vegf抗体およびその使用
JP2025503707A5 (enExample)
WO2023134771A1 (zh) 抗ctla-4抗体药物组合物及其用途
CN111108122B (zh) 抗体变体
US20250122286A1 (en) Antibody optimization
WO2025076131A1 (en) Compostions of multispecific antigen binding polypeptides and methods of use
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
TW202313693A (zh) 一種cdc平臺抗體
JP2025094941A (ja) Lag-3アゴニスト抗体